The Clinical, Molecular, and Mechanistic Basis of RUNX1 Mutations Identified in Hematological Malignancies

被引：18
|
作者：
Yokota, Asumi [1 ,2 ]
Huo, Li [1 ,2 ,3 ]
Lan, Fengli [1 ,2 ,4 ]
Wu, Jianqiang [1 ,2 ]
Huang, Gang [1 ,2 ]
机构：
[1] Cincinnati Childrens Hosp Med Ctr, Div Pathol, Cincinnati, OH 45229 USA
[2] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA
[3] Soochow Univ, Jiangsu Inst Hematol, Key Lab Thrombosis & Hemostasis, Minist Hlth,Affiliated Hosp 1, Suzhou 215006, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pediat, Wuhan 430022, Peoples R China
来源：
MOLECULES AND CELLS | 2020年 / 43卷 / 02期
关键词：
clinical incidence and prognosis; pathogenesis; RUNX1; mutations; targeted therapy; ACUTE MYELOID-LEUKEMIA; FAMILIAL PLATELET DISORDER; CHRONIC MYELOMONOCYTIC LEUKEMIA; POINT MUTATIONS; MYELODYSPLASTIC SYNDROME; SOMATIC MUTATIONS; AML1/PEBP2-ALPHA-B GENE; HEMATOPOIETIC STEM; PROGNOSTIC MODEL; CLONAL EVOLUTION;
D O I：
10.14348/molcells.2019.0252
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
RUNX1 plays an important role in the regulation of normal hematopoiesis. RUNX1 mutations are frequently found and have been intensively studied in hematological malignancies. Germline mutations in RUNX1 cause familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML). Somatic mutations of RUNX1 are observed in various types of hematological malignancies, such as AML, acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), myeloproliferative neoplasm (MPN), chronic myelomonocytic leukemia (CMML), and congenital bone marrow failure (CBMF). Here, we systematically review the clinical and molecular characteristics of RUNX1 mutations, the mechanisms of pathogenesis caused by RUNX1 mutations, and potential therapeutic strategies to target RUNX1-mutated cases of hematological malignancies.
引用
收藏
页码：145 / 152
页数：8
相关论文
共 50 条
  • [21] RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features
    Gaidzik, V. I.
    Teleanu, V.
    Papaemmanuil, E.
    Weber, D.
    Paschka, P.
    Hahn, J.
    Wallrabenstein, T.
    Kolbinger, B.
    Koehne, C. H.
    Horst, H. A.
    Brossart, P.
    Held, G.
    Kuendgen, A.
    Ringhoffer, M.
    Goetze, K.
    Rummel, M.
    Gerstung, M.
    Campbell, P.
    Kraus, J. M.
    Kestler, H. A.
    Thol, F.
    Heuser, M.
    Schlegelberger, B.
    Ganser, A.
    Bullinger, L.
    Schlenk, R. F.
    Doehner, K.
    Doehner, H.
    LEUKEMIA, 2016, 30 (11) : 2160 - 2168
  • [22] Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA)
    Brown, Anna L.
    Hahn, Christopher N.
    Scott, Hamish S.
    BLOOD, 2020, 136 (01) : 24 - 35
  • [23] Molecular Mechanisms That Produce Secondary MDS/AML by RUNX1/AML1 Point Mutations
    Harada, Yuka
    Harada, Hironori
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2011, 112 (02) : 425 - 432
  • [24] Platelet transcriptome analysis in patients with germline RUNX1 mutations
    Palma-Barqueros, Veronica
    Bastida, Jose Maria
    Andreo, Maria Jose Lopez
    Zamora-Canovas, Ana
    Zaninetti, Carlo
    Ruiz-Pividal, Juan Francisco
    Bohdan, Natalia
    Padilla, Jose
    Teruel-Montoya, Raul
    Marin-Quilez, Ana
    Revilla, Nuria
    Sanchez-Fuentes, Ana
    Rodriguez-Alen, Agustin
    Benito, Rocio
    Vicente, Vicente
    Iturbe, Teodoro
    Greinacher, Andreas
    Lozano, Maria Luisa
    Rivera, Jose
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2023, 21 (05) : 1352 - 1365
  • [25] Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML
    Stengel, A.
    Kern, W.
    Meggendorfer, M.
    Nadarajah, N.
    Perglerova, K.
    Haferlach, T.
    Haferlach, C.
    LEUKEMIA, 2018, 32 (02) : 295 - 302
  • [26] RUNX1 mutations are rare in chronic phase polycythaemia vera
    Butcher, Carolyn M.
    Neufing, Petra J.
    Eriksson, Lena
    Carmichael, Catherine L.
    Wilkins, Ella J.
    Melo, Junia V.
    Lewis, Ian D.
    Bardy, Peter G.
    Scott, Hamish S.
    D'Andrea, Richard J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (05) : 672 - 675
  • [27] SF3B1 Mutations in Hematological Malignancies
    Cilloni, Daniela
    Itri, Federico
    Bonuomo, Valentina
    Petiti, Jessica
    CANCERS, 2022, 14 (19)
  • [28] Validation and clinical application of transactivation assays for RUNX1 variant classification
    Decker, Melanie
    Agarwal, Anupriya
    Benneche, Andreas
    Churpek, Jane
    Duployez, Nicolas
    Duvall, Adam
    Ernst, Martijn P. T.
    Foerster, Alisa
    Hoberg-Vetti, Hildegunn
    Hofmann, Inga
    Nash, Michelle
    Raaijmakers, Marc H. G. P.
    Tvedt, Tor H. A.
    Vlachos, Adrianna
    Schlegelberger, Brigitte
    Illig, Thomas
    Ripperger, Tim
    BLOOD ADVANCES, 2022, 6 (11) : 3195 - 3200
  • [29] Accurate germline RUNX1 variant interpretation and its clinical significance
    Feurstein, Simone
    Zhang, Liying
    DiNardo, Courtney D.
    BLOOD ADVANCES, 2020, 4 (24) : 6199 - 6203
  • [30] Clinical characteristics and platelet phenotype in a family with RUNX1 mutated thrombocytopenia
    Botero, Juliana Perez
    Chen, Dong
    Cousin, Margot A.
    Majerus, Julie A.
    Coon, Lea M.
    Kruisselbrink, Teresa M.
    Klee, Eric W.
    Lazaridis, Konstantinos N.
    Pruthi, Rajiv K.
    Patnaik, Mrinal M.
    LEUKEMIA & LYMPHOMA, 2017, 58 (08) : 1963 - 1967
12345